Clinical Trials on in Situ Breast Cancer

Total 45737 results

Andrea DeCensi
European Institute of Oncology; Associazione Italiana per la Ricerca sul Cancro

Active, not recruiting

Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia - Long Term Follow-up (TAM-01)

Breast Neoplasms | Carcinoma, Intraductal, Noninfiltrating | Recurrence, Local Neoplasm | Atypical Hyperplasia

Italy
Abramson Cancer Center of the University of Pennsylvania
National Cancer Institute (NCI)

Completed

Partial Breast Radiation Therapy in Treating Women Undergoing Breast Conservation Therapy for Early-Stage Breast Cancer

Breast Cancer | Long-term Effects Secondary to Cancer Therapy in Adults | Skin Reactions Secondary to Radiation Therapy

United States
Finn, Olivera, PhD
Breast Cancer Research Foundation; A Glimmer of Hope Foundation

Recruiting

Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ

Ductal Carcinoma in Situ

United States
University of Chicago

Terminated

A Pilot Study of Chemo-prevention of Green Tea in Women With Ductal Carcinoma in Situ

Ductal Carcinoma in Situ

United States
QuantumLeap Healthcare Collaborative

Recruiting

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

Ductal Carcinoma in Situ

United States
Glendale Adventist Medical Center d/b/a Adventist...
Helen Rey Breast Cancer Research Foundation; California Oncology Research Institute and other collaborators

Recruiting

Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ (DCIS)

Ductal Carcinoma in Situ

United States
Larkin Community Hospital

Withdrawn

Subzero and Scorpion Trial

Ductal Carcinoma in Situ

United States
Yale University

Completed

A Pilot Pre-operative Window Trial of Black Cohosh in Women With Ductal Carcinoma in Situ

Ductal Carcinoma in Situ

United States
NYU Langone Health

Terminated

Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor

Ductal Carcinoma in Situ

United States
Northwestern University
National Cancer Institute (NCI); Amgen

Terminated

Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells

Stage IV Breast Cancer | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Positive | Breast Carcinoma Metastatic in the Bone | Circulating Tumor Cell Count

United States
Seagen Inc.

Completed

A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer

HER2 Positive Breast Cancers

United States, Canada
University of Washington

Terminated

Occupational Therapist-Led Work Intervention in Facilitating Work Maintenance or Re-entry to the Workforce in Patients With Stage I to III Breast Cancer Undergoing Chemotherapy

Breast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIc

United States
Ohio State University Comprehensive Cancer Center

Completed

Aerobic and Strength Training Exercise in Improving Fitness and Arm Health During and After Radiation Therapy in Patients With Stage II-III Breast Cancer

Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Stage III Breast Cancer

United States
University of Southern California
National Cancer Institute (NCI)

Terminated

High-Intensity Interval Training for Stage I-III Breast Cancer Patients

Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer

United States
Ontario Clinical Oncology Group (OCOG)

Recruiting

Prospective Evaluation of Breast-Conserving Surgery Alone in Low-Risk Ductal Carcinoma in Situ (DCIS) (ELISA)

DCIS

Canada
Alliance Foundation Trials, LLC.
Patient-Centered Outcomes Research Institute; M.D. Anderson Cancer Center; Washington... and other collaborators

Active, not recruiting

Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) Trial For Low Risk DCIS (COMET)

Ductal Carcinoma in Situ | DCIS

United States
Hologic, Inc.
University of Southern California

Completed

MammoSite as Sole Radiation Therapy Technique for Ductal Carcinoma In-Situ (DCIS)

DCIS

United States
Albert Einstein College of Medicine
National Cancer Institute (NCI)

Active, not recruiting

Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer

Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer

United States
Olema Pharmaceuticals, Inc.
Novartis

Recruiting

Phase 1b Combo w/ Ribociclib and Alpelisib

Advanced Breast Cancer | Metastatic Breast Cancer | HR-positive Breast Cancer | HER2-negative Breast Cancer

United States, Australia
Stanford University

Terminated

Pilot Study to Determine Radioiodide Accumulation and Dosimetry in Breast Cancers Using 124I PET/CT

Breast Cancer | Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Breast Cancer Metastatic Breast Cancer

United States
City of Hope Medical Center

Terminated

Feasibility of a Supportive Education Program for Latina Breast Cancer Survivors

Stage I Breast Cancer | Cancer Survivor | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer

United States
Mayo Clinic

Recruiting

Tumor Treating Fields for the Treatment of Leptomeningeal Metastases of the Spine in Patients With Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Breast Carcinoma | Metastatic Malignant Neoplasm in the Leptomeninges

United States
University of Southern California
National Cancer Institute (NCI)

Terminated

PET/CT in Evaluating Response to Chemotherapy in Patients With Breast Cancer

HER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer

United States
University of Washington
National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery

HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...

United States
European Institute of Oncology

Recruiting

LobularCard Trial: Searching for Novel Germline Mutations in Lobular Breast Cancer Patients (LobularCard)

BRCA1 Mutation | BRCA2 Mutation | Lobular Breast Carcinoma | Lobular in Situ Breast Carcinoma

Italy
Hoffmann-La Roche

Withdrawn

A Study To Observe Treatment Patterns and Outcomes in Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Breast Cancer, HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer
Masaryk University
Masaryk Memorial Cancer Institute

Recruiting

The Effectiveness of Psychological Interventions in Psycho-neuroendocrine-immune Network in Breast Cancer Survivors

Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III

Czechia
University of Chicago

Recruiting

Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer

Breast Cancer | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III

Nigeria
Stanford University
National Institutes of Health (NIH); University of California; Breast Cancer... and other collaborators

Active, not recruiting

Molecular Analysis of Breast Cancer

Breast Cancer | Breast Cancer Non-invasive Breast Cancer | Breast Cancer Early Stage Breast Cancer (Stage 1-3)

United States
University of Nebraska
National Cancer Institute (NCI)

Terminated

Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer

Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | HER2-negative Breast Cancer

United States
University of Southern California
National Cancer Institute (NCI)

Completed

Exercise Program for Early Breast Cancer Survivors

Stage I Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer

United States
National Cancer Institute (NCI)

Completed

Celecoxib in Treating Postmenopausal Women Who Are Undergoing Surgery for Invasive Breast Cancer

Stage I Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer

United States
North Central Cancer Treatment Group
National Cancer Institute (NCI)

Completed

Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ

Breast Cancer | Radiation Toxicity | Skin Reactions Secondary to Radiation Therapy | Dermatologic Complications

United States
National Cancer Institute (NCI)

Terminated

Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer

Male Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer

United States
National Taiwan University Hospital

Recruiting

Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC

Metastatic Breast Cancer | Premenopausal Breast Cancer | ER Positive Breast Cancer

Taiwan
MedSIR
MacroGenics; Seagen Inc.

Withdrawn

Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer (MARGARET)

Advanced Breast Cancer | Metastatic Breast Cancer | HER2-positive Breast Cancer
Washington University School of Medicine
National Cancer Institute (NCI)

Terminated

Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer

Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-positive Breast Cancer | HER2-negative Breast Cancer

United States
Kimberly Blackwell

Terminated

Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer

HER2 Positive Untreated Metastatic Breast Cancer | Asymptomatic or Low Symptomatic Brain Metastasis in Breast Cancer

United States
Innocrin Pharmaceutical

Completed

CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448) (CLARITY-01)

Breast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the Breast

United States
University of Colorado, Denver

Active, not recruiting

Window of Opportunity Study Targeting the Inflammatory Milieu

Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI); Rutgers Cancer Institute of New Jersey

Active, not recruiting

Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer

Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast Cancer

United States
University of Southern California
National Cancer Institute (NCI)

Terminated

Endoscopic Breast Surgery in Treating Patients With Breast Cancer

Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer

United States
Emory University
National Cancer Institute (NCI)

Recruiting

Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab

Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Invasive | Breast Cancer Triple Negative

United States
Massachusetts General Hospital
Gilead Sciences

Recruiting

Sacituzumab Govitecan In TNBC (NeoSTAR)

Triple Negative Breast Cancer | Invasive Breast Cancer | HER2-negative Breast Cancer | ER-Negative Breast Cancer | PR-Negative Breast Cancer

United States
University of Washington
National Cancer Institute (NCI)

Terminated

FDG PET and DCE-MRI in Predicting Response to Treatment in Patients With Breast Cancer

Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer

United States
National Cancer Institute (NCI)

Completed

Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer

Inflammatory Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer

United States
Institut fuer Frauengesundheit
Novartis Pharmaceuticals; AGO Breast Study Group e.V.

Recruiting

Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients (CAPTOR-BC)

Breast Cancer | Breast Neoplasms | Advanced Breast Cancer | Breast Neoplasm Female | Breast Cancer Female | HER2-negative Breast Cancer | Hormone Receptor-positive Breast Cancer

Germany
University of Washington
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer

HER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...
Susan G. Komen Breast Cancer Foundation

Completed

Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer

Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast Cancer

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI); Synta Pharmaceuticals Corp.; New York University...

Completed

Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer

HER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer

United States

Clinical Trials on in Situ Breast Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Kingdom

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations